Dotarem Training Feb 05
-
Upload
monolith4200 -
Category
Documents
-
view
368 -
download
2
Transcript of Dotarem Training Feb 05
![Page 1: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/1.jpg)
DOTAREM®
T. PEYROUX – February 2005
![Page 2: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/2.jpg)
Parameters contributingto contrast
proton density
relaxation time T1
relaxation time T2
![Page 3: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/3.jpg)
Contrast agents
proton density
water, etc. (stomach. intestine)
T1 and T2
interaction with electrons
![Page 4: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/4.jpg)
Proton relaxation
years in vacuum
seconds in presence of protons
µsec in presence of electrons
![Page 5: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/5.jpg)
Paramagnetic ions
Ti2+
Cr3+
Mn2+
Fe3+
Fe2+
Co2+
Ni2+
Cu2+
Gd3+
CONFIGURATION No. of SPINSELEMENT
Among the metals possessing unpaired electrons, gadolinium, manganese and iron appear the most powerful with
7, 5 and 5 unpaired electrons, respectively
![Page 6: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/6.jpg)
Injected intravenously, it is rapidly distributed throughout
water and does not target any particular organ
DOTAREM is a « non specific » agent
![Page 7: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/7.jpg)
Pharmacokinetic properties
DOTAREM is a small and hydrophilic complex so it has a pharmacokinetic behaviour quite similar to water-soluble X-ray contrast agent: bicompartmental model without metabolization and passiverenal glomerular filtration.
VESSELS
BBB
cellularcompartment
IV injection
Renal elimination (glomerular filtration)
Interstitium
![Page 8: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/8.jpg)
T1 effect
After injection, the complexes decrease the T1 time
Time
Mz
Spontaneous T1 (without Gd)
Final T1 after paramagnetic complex injection
My
signal
![Page 9: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/9.jpg)
Prolactinoma
Pre-contrast Post-DOTAREM
![Page 10: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/10.jpg)
68 y/o man with headacheA large, meningeal-based mass is seen in the right frontal lobe that is dark on T1-weighted image.With Gadolinium, marked homogeneous enhancement is seen in the mass.
T1-weighted without contrast agent T1-weighted with gadolinium
![Page 11: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/11.jpg)
DOTAREM is a gadolinium complex
with paramagnetic properties
=
O
Gd3+......
............
......N
N
N
N
O-
_ __ ___ ______ ______________________
_ __ ___ ______ ______________________
_ __ ___ ______ ______________________
O-
O-
O C = OO = C
=
C
C
O
_
_
_
___
____
__ _
____
____
___
____
____
__
H
![Page 12: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/12.jpg)
DOTAREM is a gadolinium complex
![Page 13: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/13.jpg)
Why a complex and nota simple gadolinium salt?
Gd3+
- lower relaxivity- reduced H2O binding sites- improved tolerance LD 50 mouse: 10.6 mmol/kg LD 50 rat: > 12.5 mmol/kg
Gd3+
H2O
- higher relaxivity- more interaction with water- highly toxic LD 50 mouse: 0.4 mmol/kg LD 50 rat: 1.6 mmol/kg i.p.
![Page 14: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/14.jpg)
Why is gadolinium toxic?
Gd3+
diameter of ionic sphere1.02 A
Ca2+
diameter of ionic sphere0.99 A
1. Calcium antagonistic effect: no intrinsic activity on calcium channel:myocardial contraction, ATPase, inhibition of coagulation, cellular respiratory system, reduction of calcium.
2. precipitation of Gd(HO)3 at a pH above 6.4: RES blockage
![Page 15: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/15.jpg)
Chemical structure of the complexes
Gd3+
N N
N N
OH
COO-
- O OC
- O OC
HP-DO3A-Gd(PROHANCE®)
DOTA-Gd
(DOTAREM®)
Gd3+
N N
N NCOO-- O OC
- O OC CO O -
DTPA-Gd(MAGNEVIST®)
COO-
N N NCOO--OO C
COO--OOC
Gd3+
DTPA-BMA-Gd(OMNISCAN®)
Gd3+
COO-
N N
COO-CH3
N
O
CH3N
HO
COO-
H
2HO
Gd3+
N N
COO-
OCOO-
N
COO-
COO-
COO-
CH3
H2N+
HOHO
HO
HO
BOPTA-Gd(MULTIHANCE®)
![Page 16: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/16.jpg)
Gadoversetamide (Optimark®)
Chemical structure of the complexes (cont’d)
![Page 17: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/17.jpg)
Two classes of Gadolinium chelates are availableScientific name structure Commercial name Company
dimegluminegadopentate
gadodiamide
gadoversetamide
linear / ionicGd-DTPA
linear / nonionicGd-DTPA BMA
Linear / nonionic
Magnevist®
Omniscan®
Optimark®
Schering
GE Healthcare
megluminegadoterate
Macrocyclic/ionicGd-DOTA
DOTAREM® Guerbet
Tyco
Multihance® BraccoLinear / ionicGd-BOPTA
dimegluminegadobenate
![Page 18: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/18.jpg)
Relaxivity
Gadolinium complexes have equivalent paramagnetic efficacy
Complexes r1 (T1) BloodT1 (msec)
Gd-DOTA (DOTAREM®)
Gd-DTPA (Magnevist®)
Gd-HP DO3A (Prohance®)
Gd-DTPA BMA (Omniscan®)
Gd-BOPTA (Multihance®)
3.4
3.44
3.7
3.9
4.39
24.5
20.4
18.5
18.5
10.3
Variation(%)
97.95
98.30
98.45
98.45
99.74
![Page 19: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/19.jpg)
Viscosity
-4.93.22.82.0
Viscosity20°C
(mPa.s)
Multihance®
Magnevist®
DOTAREM®
Omniscan®
Prohance®
0.5 M
5.32.92.01.91.3
Viscosity37°C
(mPa.s)
![Page 20: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/20.jpg)
Is osmolality a problem
in MRI?
![Page 21: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/21.jpg)
Osmolality
The increase in plasmatic osmolality following injection of an MRI contrast agent is much lower than that induced by even a low osmolality iodinated agent.
Osmolality
(mOsm/kg)
Osmoticload*
(mOsm)
Increase in plasmaticosmolality**(mOsm/kg)
Gd-BOPTAGd-DTPAGd-DOTAGd-DTPA BMAGd-HP DO3A
iodinated HOCM
iodinated LOCM
0.5 M
350 gI/L
320 gI/L
197019401350 789 630
2160
600
27.427.018.911.0 8.8
302.4
84
1.51.51.10.60.5
17.28
4.8
* clinical dose = 0.2 ml/kg (MRI) or 2 ml/kg (X-ray)**supposing an instantaneous distribution of the extracellular water
![Page 22: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/22.jpg)
Complex dissociation
Gd[Ligand] [Ligand] + Gd3+
![Page 23: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/23.jpg)
Stability of Gd complexes
ComplexesThermodynamic
stability(logK)
Half-lifein a 0.1M HCLacid solution
Gd-DOTA(DOTAREM®)
Gadoversetamide(Optimark)
Gd-BOPTA(Multihance)
Gd-DTPA(Magnevist)
Gd-DTPA BMA(Omniscan)
25.8
16.6
22.6
22.1
16.9
up to 1 month
NA
NA
10 min.
30 sec
Apparent stabilitypH 7.4(logK)
18.8
14.9
18.4
17.7
14.9
(Tweedle M.F. Invest. Radiology, 1992; vol 27 suppl 1/S2-6)
DOTAREM, macrocyclic and ionic, is the most stable, irrespective of the measurement method
![Page 24: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/24.jpg)
Transmetallation
The more stable the complex, the lower the number of dissociationand exchange reactions with endogenous ions (transmetallation)
ComplexesZn2+
(2mM, 15 min)Cu2+
(2 mM, 15 min)
Gd-DTPA (Magnevist®)
Gd-DTPA BMA (Omniscan®)
Gd-HP DO3A (Prohance®)
Gd-DOTA (DOTAREM®)
21 %
25 %
< 1%
< 1 %
25 %
35 %
< 1 %
< 1 %
![Page 25: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/25.jpg)
Macrocycles have a reduced transmetallation andare thus more stable
What is Transmetallation?
Gd[Ligand] + Mex+ Me[Ligand] + Gd3+
If we add electrolytes to a gadolinium complex, thesemetal ions interact with the ligand chelator and tend toliberate free gadolinium.
![Page 26: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/26.jpg)
% Retention in the femur at 14 days(Mice, 0.4 mmol/kg)
0
0,02
0,04
0,06
0,08
0,1
DOTA HP DO3A DTPA DTPABMA
< sens < sens
Tweedle 1992
![Page 27: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/27.jpg)
Advantages of DOTAREM
Stability and transmetallation
DOTAREM, Gd-DOTA, macrocyclic and ionicis the most stable Gd3+ complex with the lowest
risk of transmetallation
![Page 28: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/28.jpg)
Interference with calcium measurement(J. Lin et coll. 1999)
-18
-16
-14
-12
-10
-8
-6
-4
-2
0
2
time (sec)
-1
4
9
14
19
24
29
34
39
44
49
time (sec)
Variation (in %) of UV absorbance ofO-cresol-phtalein (commercial solution)at 572 nm over time in the presence ofGd-DOTA (2,5 mM) or Gd-DTPA-BMA(2,5 mM).
OCP/Gd-DTPA-BMA OCP/Gd-DOTA OCP alone
Variation (in %) of UV absorbance ofmethylthymol blue (commercial solution)at 612 nm over time in the presence ofGd-DOTA (2,5 mM) or Gd-DTPA-BMA(2,5 mM).
OCP/Gd-DTPA-BMA OCP/Gd-DOTA OCP alone
Cha
nge
in U
V a
bsor
banc
e
Cha
nge
in U
V a
bsor
banc
e
![Page 29: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/29.jpg)
Interference with calcium measurement(J. Lin et coll. 1999)
Ch
an
ge
in U
V a
bso
rba
nce
![Page 30: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/30.jpg)
Retrospective study (22-month period): 1049 patients
«Spurious» hypocalcemia in the majority of the patients
«Critical» hypocalcemia (<6 mg/dl): 33 patients (3.1%)
False “critical” Hypocalcemia following Gadodiamide Infusion
(Hale E. EREL & coll. 2002)
18 treatments
7 (IV) 11 (oral)
![Page 31: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/31.jpg)
Pharmaceutical formulations of thedifferent commercial solutions
Commercial solutions Pharmaceutical formulations
DOTAREM®
PROHANCE®
MAGNEVIST®
OMNISCAN®
No Ca2+ complex added
0.1 % in moles of Ca2+ HP DO3Acalcium salt
0.2 % in moles of DTPAmeglumine salt
5 % in moles of Ca2+ DTPA BMAsodium salt
![Page 32: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/32.jpg)
MACROCYCLIC / LINEAR (stability)
is a better classification than
IONIC / NON-IONIC (osmolality)
![Page 33: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/33.jpg)
Studies Patients Adverse events
Caillé's paper (1991) 4169 0.84 %
Oudkerk's paper (1995) 1038 0.97 %
DOTAREM Tolerance
![Page 34: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/34.jpg)
Indications(according to the countries)
Central Nervous System
![Page 35: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/35.jpg)
Prolactinoma
Pre-contrast Post-DOTAREM
![Page 36: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/36.jpg)
A 56-year-old female patient with a history of myeloma. Diplopia and left exophthalmus developed in four days. Axial T1- and T2-weighted sequences showed an extra conal tumoral process in the superior lateral left orbit that lowered the globe. After injection of Dotarem®, the lesion markedly enhanced whereas no intracranial involvement or meningeal uptake was visualised. Biopsy diagnosed a plasmacytoma
axial T1 w. sequence axial T1 post DOTAREM®
![Page 37: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/37.jpg)
Leptomeningeal metastases
Post-DOTAREM
![Page 38: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/38.jpg)
Assessment of low back pain with fever in a Pakistani male patient. T1- and T2-weighted sequences were used, and a T1-weighted sequence after injection of Dotarem®. Tuberculous spondylitis with paravertebral abscesses were easily diagnosed. The epidural abscess was clearly visible after injection of Dotarem®.
sagital T1w. sequence sagital T1 post DOTAREM ®
![Page 39: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/39.jpg)
Indications(according to the countries)
Central Nervous System
Whole Body (abdomen, kidneys, pelvis, heart, mammae, joint diseases)
![Page 40: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/40.jpg)
Dynamic imaging
Dynamic MRI of left breast
![Page 41: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/41.jpg)
Bone-joint examinations
20-year-old man with right femoral pain with nocturnal recrudescence
Pre-contrast Post-Dotarem
![Page 42: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/42.jpg)
Bone-joint examinations
A 47-year-old immunodepressed male patient presented with a painful swelling on the medial left knee in a context of deteriorated general health status. T2-, T1- and fat-suppressed proton-density-weighted sequences (1 to 4) showed both bone and joint involvement. The sequences after injection of Dotarem® (5 and 6) showed epiphyseal and synovial contrast uptake. Biopsy resulted in a diagnosis tuberculosis osteomyelitis and arthritis.
sagital T1 w. sequence sagital T1 post DOTAREM ®
![Page 43: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/43.jpg)
Bone-joint examinations (cont'd)
25-year-old patient with inflammatory knee pain
Pre-contrast Post-Dotarem
![Page 44: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/44.jpg)
Central Nervous System
Whole Body (abdomen, kidneys, pelvis, heart, mammae, joint diseases)
Angiography
Indications(according to the countries)
![Page 45: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/45.jpg)
Postoperative assessment of a femoro-femoral by-pass in a 55-year-old patient.
58-year-old patient with diabetes mellitus and peripheral arterial disease
Peripheral angiography
![Page 46: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/46.jpg)
Peripheral angiographyA 72-year-old male patient, a heavy smoker, presented with left intermittent claudication beyond a 500-metre range. The examination showed that the left femoral pulse was reduced and the systolic blood pressure of the lower limbs was four points lower on the left side. MR angiography carried out with a bolus injection of 20 cc of Dotarem® shows a very short pre-occlusive stenosis at the origin of the left common iliac artery and stenoses of both internal iliac arteries. Images of the distal bed only showed moderate infiltration of the arteries without significant stenosis. Thus, the patient was scheduled for angioplasty of the left common iliac artery.
iliac MRA thigh MRA legs MRA
![Page 47: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/47.jpg)
Carotid arteries imaging
TOF MR angiography fails to provide sufficient diagnostic information
Contrast enhanced MR angiography
![Page 48: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/48.jpg)
Renal transplantation follow-up41-year-old male patient with renal insufficiency and hypertension
Renal imaging
![Page 49: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/49.jpg)
Patient with severe atherosclerosis, arrows indicate bilateral renal artery sclerosis
![Page 50: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/50.jpg)
Posology and method of administration
(according to the countries)
The standard dose is 0.1 mmol/kg i.e. 0.2 ml/kg
Angiography: a second injection of 0.2 ml/kg may beadministered during the same session if necessary
Cerebral explorations in oncology: a second injectionof 0.4 ml/kg can be administered
![Page 51: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/51.jpg)
DOTAREM is the first product to have obtained
MR Angiography indication
![Page 52: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/52.jpg)
Vials: 5 ml, 10 ml, 15 ml, 20 ml, 60 ml, 100 ml
Prefilled syringes: 15 ml, 20 ml
Future (to be determined)- 10 ml prefilled syringe- 40 ml vial
DOTAREM®
A large range of packaging forms(according to the countries)
![Page 53: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/53.jpg)
Used in more than 5 Million examinations
Extremely well tolerated
For all ages, whole body and angiography (according to the countries)
A large range of packaging forms
Compatible with all new sequences
DOTAREM®
![Page 54: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/54.jpg)
Comparison Dotarem® / competitors (1)
Trademark Dotarem® Guerbet Magnevist® Schering
Omniscan® Amersham
Multihance® Bracco/Altana
OptiMARK®
Tyco
Scientific name
Gd-DOTA Gd-DTPA Gd-DTPA BMP Gd-BOPTA Gadoversetamide
Structure nature
Macrocyclic ionic Linear ionic Linear non ionic Linear ionic Linear nonionic
Osmolality mOsm/kg
1350 1960 650 1970 1110
Viscosity at 37°C
2.0 2.9 1.4 5.4 2
Thermodyn. Stability
25.8 22.1 16.9 22.6 16.6
Practical Packaging
Vials : 5, 10, 15, 20, 60 & 100 ml
Syringes :
15 & 20 ml
Vials : 5, 10, 15, 20, 30 & 100 ml
Syringes :10, 15 & 20 ml
Vials : 5, 10, 15, 20, 50 ml
Syringes : 10, 15 & 20 ml
Vials : 5, 10, 15 & 20 ml
Vials: 5,10,15 & 20 ml
Syringes: 10,15,20 & 30 ml
![Page 55: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/55.jpg)
Comparison Dotarem® / competitors (2)
Trademark Dotarem®
GuerbetMagnevist® Schering
Omniscan® Amersham
Multihance ® Bracco/Altana
OptiMARK®
Tyco
Authorized administration
Adults
Children
Infants
Adults
Children
Infants
Adults
Children
Infants
Adults Adults
Indications - Neuro- Whole body- Angiography
- Neuro- Whole body
- Neuro- Whole body- Angiography
- Liver lesions- Neuro
- Neuro - Liver
Dosage mmol/kg
- 0.1- 0.1 + 0.2- 0.1 + 0.2
- 0.1- 0.1 + 0.1- 0.3
- 0.1- 0.1 + 0.2- 0.1 + 0.1 + 0.1
- Liver: 0.05
- CNS: 0.1
- 0.1
![Page 56: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/56.jpg)
Comparison Dotarem® / competitors (3)
Trademark Dotarem®
GuerbetMagnevist® Schering
Omniscan® Amersham
Multihance ® Bracco/Altana
OptiMARK®
Tyco
Contra Indications (other than Gd, pacemarker, Vascul. Clip)
0 Haemolitic anaemia
0 - Severe renal failure- Pregnant women
Allergy to Gd
Special warnings & special precautions for use
- Caution in patients with severe renal failure
- Observation of renal fc in patients with renal failure-Patients with convulsive antecedents
Caution in patients with several renal failure
- not recommended < 18 years- Caution in patients with cardiovascular pathologies
Haemoglobino-pathies
Interaction - Modif. Calcium dosage
- Modif. Calcium dosage
![Page 57: Dotarem Training Feb 05](https://reader035.fdocuments.in/reader035/viewer/2022081414/54ffd9ab4a7959e6728b4d14/html5/thumbnails/57.jpg)
Comparison Dotarem® / competitors (4)
Trademark Dotarem®
GuerbetMagnevist® Schering
Omniscan® Amersham
Multihance® Bracco/Altana
OptiMARK®
Tyco
Relaxivity r1 (mM -1 sec-1) water
3.4 3.77 3.8 4.39
Relaxivity r1 (mM -1 sec-1) blood
4.0 4.8 5.4 9.7
T1 blood (msec)
24.5 20.4 18.5 10.3
Variation (%) 97.95 98.30 98.45 99.14